CAR-T cell therapy for progressive multiple sclerosis
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial is testing a type of immunotherapy called CAR-T cells (made from your own immune cells) to see if it can help slow or stop progressive multiple sclerosis. It is a very early safety study, so only people with progressive MS who meet strict health criteria can join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must have progressive multiple sclerosis (not relapsing-remitting).
- You need to have protection against shingles (from the Shingrix vaccine or prior infection).
- You must have antibodies to Epstein-Barr virus (EBV).
- Your organs (like heart, liver, kidneys, and lungs) must be working well enough.
- You cannot have certain past treatments, like stem cell transplant, CAR T, or anti-CD20 therapy within 9 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called S103 for people with MS that isn't responding well to standard treatments. The therapy involves modifying immune cells in the lab and putting them back into your body to help control the disease.
This study tests an experimental treatment called C-CAR168, which uses your own immune cells that have been modified to target and potentially slow down the progression of multiple sclerosis. It is for younger adults with progressive MS who have not responded well to standard treatments.
This trial tests a new treatment called MB-CART2019.1, which uses your own immune cells to fight multiple sclerosis. It is for people with progressive or worsening MS who have not responded well to other treatments.
This early-stage trial uses a type of immune cell therapy (CAR-T cells) to treat severe autoimmune diseases that attack the nervous system, such as NMOSD, myasthenia gravis, CIDP, and multiple sclerosis. The goal is to see if this treatment can stop the immune system from damaging nerves when other treatments have failed.
This study tests a new treatment using a patient's own immune cells, modified to fight the immune system's attack on the nervous system. It aims to slow or stop the progression of multiple sclerosis when standard treatments have not worked.
This trial tests a new cell therapy called C-CAR168, which uses a patient's own immune cells to target and potentially reset the immune system to treat conditions like multiple sclerosis, lupus, and myasthenia gravis. It's for people whose disease has not improved with standard treatments.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.